Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms - PubMed (original) (raw)
Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms
M L Dubocovich et al. FASEB J. 1998 Sep.
Abstract
This study demonstrates the involvement of the MT2 (Mel1b) melatonin receptor in mediating phase advances of circadian activity rhythms by melatonin. In situ hybridization histochemistry with digoxigenin-labeled oligonucleotide probes revealed for the first time the expression of mt1 and MT2 melatonin receptor mRNA within the suprachiasmatic nucleus of the C3H/HeN mouse. Melatonin (0.9 to 30 microg/mouse, s.c.) administration during 3 days at the end of the subjective day (CT 10) to C3H/HeN mice kept in constant dark phase advanced circadian rhythms of wheel running activity in a dose-dependent manner [EC50=0.72 microg/mouse; 0.98+/-0.08 h (n=15) maximal advance at 9 microg/mouse]. Neither the selective MT2 melatonin receptor antagonists 4P-ADOT and 4P-PDOT (90 microg/mouse, s.c.) nor luzindole (300 microg/mouse, s.c.), which shows 25-fold higher affinity for the MT2 than the mt1 subtype, affected the phase of circadian activity rhythms when given alone at CT 10. All three antagonists, however, shifted to the right the dose-response curve to melatonin, as they significantly reduced the phase shifting effects of 0.9 and 3 microg melatonin. This is the first study to demonstrate that melatonin phase advances circadian rhythms by activation of a membrane-bound melatonin receptor and strongly suggests that this effect is mediated through the MT2 melatonin receptor subtype within the circadian timing system. We conclude that the MT2 melatonin receptor subtype is a novel therapeutic target for the development of subtype-selective analogs for the treatment of circadian sleep and mood-related disorders.
Similar articles
- Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock.
Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Hunt AE, et al. Am J Physiol Cell Physiol. 2001 Jan;280(1):C110-8. doi: 10.1152/ajpcell.2001.280.1.C110. Am J Physiol Cell Physiol. 2001. PMID: 11121382 - Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice.
Rawashdeh O, Hudson RL, Stepien I, Dubocovich ML. Rawashdeh O, et al. Chronobiol Int. 2011 Feb;28(1):31-8. doi: 10.3109/07420528.2010.532894. Chronobiol Int. 2011. PMID: 21182402 Free PMC article. - Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse.
Masana MI, Benloucif S, Dubocovich ML. Masana MI, et al. J Pineal Res. 2000 Apr;28(3):185-92. doi: 10.1034/j.1600-079x.2001.280309.x. J Pineal Res. 2000. PMID: 10739306 - Mammalian melatonin receptors: molecular biology and signal transduction.
von Gall C, Stehle JH, Weaver DR. von Gall C, et al. Cell Tissue Res. 2002 Jul;309(1):151-62. doi: 10.1007/s00441-002-0581-4. Epub 2002 May 18. Cell Tissue Res. 2002. PMID: 12111545 Review. - Molecular pharmacology, regulation and function of mammalian melatonin receptors.
Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Dubocovich ML, et al. Front Biosci. 2003 Sep 1;8:d1093-108. doi: 10.2741/1089. Front Biosci. 2003. PMID: 12957828 Review.
Cited by
- High and low dose of luzindole or 4-phenyl-2-propionamidotetralin (4-P-PDOT) reverse bovine granulosa cell response to melatonin.
Liu W, Chen Z, Li R, Zheng M, Pang X, Wen A, Yang B, Wang S. Liu W, et al. PeerJ. 2023 Jan 16;11:e14612. doi: 10.7717/peerj.14612. eCollection 2023. PeerJ. 2023. PMID: 36684672 Free PMC article. - Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans.
Rajaratnam SM, Middleton B, Stone BM, Arendt J, Dijk DJ. Rajaratnam SM, et al. J Physiol. 2004 Nov 15;561(Pt 1):339-51. doi: 10.1113/jphysiol.2004.073742. Epub 2004 Sep 30. J Physiol. 2004. PMID: 15459246 Free PMC article. Clinical Trial. - Piromelatine exerts antinociceptive effect via melatonin, opioid, and 5HT1A receptors and hypnotic effect via melatonin receptors in a mouse model of neuropathic pain.
Liu YY, Yin D, Chen L, Qu WM, Chen CR, Laudon M, Cheng NN, Urade Y, Huang ZL. Liu YY, et al. Psychopharmacology (Berl). 2014 Oct;231(20):3973-85. doi: 10.1007/s00213-014-3530-5. Epub 2014 Apr 4. Psychopharmacology (Berl). 2014. PMID: 24700387 - The effects of melatonin on bovine uniparental embryos development in vitro and the hormone secretion of COCs.
Wang S, Liu B, Liu W, Xiao Y, Zhang H, Yang L. Wang S, et al. PeerJ. 2017 Jul 7;5:e3485. doi: 10.7717/peerj.3485. eCollection 2017. PeerJ. 2017. PMID: 28698819 Free PMC article. - Melatonin Entrains PER2::LUC Bioluminescence Circadian Rhythm in the Mouse Cornea.
Baba K, Davidson AJ, Tosini G. Baba K, et al. Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4753-8. doi: 10.1167/iovs.15-17124. Invest Ophthalmol Vis Sci. 2015. PMID: 26207312 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- T32 ES 07124/ES/NIEHS NIH HHS/United States
- R01 MH042922/MH/NIMH NIH HHS/United States
- MH 52685/MH/NIMH NIH HHS/United States
- R01 MH052685/MH/NIMH NIH HHS/United States
- R01 MH042922-14/MH/NIMH NIH HHS/United States
- R01 MH052685-05/MH/NIMH NIH HHS/United States
- MH 42922/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases